Ashizawa K,Eguchi K. .2003 .Serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease receiving anti-thyroid medication. Intern Med, 42 : 463-464.
.2006 .. Expert Opin Drug Saf, 5 : 107-116.
Khursid I,Sher J .2000 .Disseminated intravascular coagulation and vasculitis during propylthiouracil therapy. Postgrad Med J, 76 : 185-186.
Sera N,Ashizawa K,Ando T,Abe Y,Ide A,Usa T .2000 .Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid, 10 : 595-599.
Harper L,Chin L,Daykin J,Allahabadia A,Heward J,Gough SC .2004 .Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf), 60 : 671-675.
Mathieu E,Fain O,Sitbon M,Thomas M. .1999 .Systemic adverse effect of antithyroid drugs. Clin Rheumatol, 18 : 66-68.
.2004 .. Propylthiouracil induced ANCA positive vasculitis: a Case Report. Int J Endocrinol Metab, 2 : 47-50.
Vasily DB,Tyler WB .1980 .Propylthiouracil-induced cutaneous vasculitis. Case presentation and review of the literature. JAMA, 243 : 458-461.
.2008 .Long-term outcomes of patients with propylthiouracilinduced anti-neutrophil cytoplasmic auto-antibodyassociated vasculitis. Rheumatology, 47 : 1515-1520.